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Abstract
A subepithelial lesion (SET) is defined as a lesion, bulge or impression visible within the 
lumen of the gastrointestinal tract that is covered by normally appearing mucosa and 
usually found incidentally during routine endoscopy. Such a lesion could be either an 
intramural mass or an impression caused by extramural structures. The old terminology 
has recently been replaced by the term “subepithelial lesion” because intramural lesions 
may arise and can be located in any layer of the GI wall underneath the epithelium. The 
most common SELs are gastrointestinal stromal tumors (GISTs), leiomyomas, lipomas, 
granular cell tumors (GCTs), pancreatic rests and carcinoid tumors. The prognosis varies 
from benign to potentially malignant. While the majority of the lesions are considered 
benign, some tumors such as GISTs and carcinoids have a strong propensity for malig-
nant transformation. Endoscopic ultrasonography (EUS) is the most accurate diagnostic 
method for distinguishing between extraluminal compressions and intramural lesions 
and plays a critical role in the detection and management of SELs. This is because EUS 
can reveal the precise sonographic nature of the lesion even though sometimes there are 
complex cases, which are difficult to diagnose by EUS alone. Performing routine biop-
sies and obtaining tissue samples for diagnosis can be difficult because SELs are located 
beneath the normal epithelial layer. Mostly, EUS allows the practitioner to extract an 
optimal tissue sample since it allows fine-needle aspiration (FNA) and fine-needle biopsy 
(FNB) both of which provide good results. With immunocytochemical staining, all these 
techniques increase the accuracy of the diagnosis. Evaluation of subepithelial lesions by 
means of EUS imaging will provide further characterization of the lesion to help guide 
us in appropriate differential diagnosis and further management. In this chapter, we pro-
vide a systematic EUS-guided approach to the diagnosis, management and later sur-
veillance for SELs, as well as presenting updated diagnostic techniques that may help 
physicians to appropriately manage these subepithelial lesions.
Keywords: endoscopy, endoscopic ultrasound (EUS), subepithelial lesion (SET), 
fine-needle aspiration (FNA), fine-needle biopsy (FNB), multidetector computed 
tomography (MDCT)
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1. Introduction
The prevalence of subepithelial lesions (SELs) detected on routine endoscopy is unknown; 
however, these are frequently encountered with 0.36% of EGD procedures. During the last 
10 years, the detection rate has increased, with advances in endoscopic technology with 
the more widespread use of EUS and close attention paid during routine endoscopy exams 
and reported with 1%, with an incidence of 1 in 300 patients [1]. The malignant lesions are 
reported with 13% accuracy [2]. Men and women are equally affected. Most of the patients 
are more than 50-year old. Usually US, CT and MRI are not sensitive enough to detect and 
characterize the majority of SELs since they can be smaller than 1 cm in size. SELs have 
a wide and diverse spectrum of etiologies (normal structures; benign lesions and malig-
nant tumor), clinical course, radiological, and understanding the endoscopic, EUS and 
underlying pathologic features of SELs is essential for their detection, differential diagno-
sis, staging and management. They are most commonly found in the stomach, esophagus 
and duodenum. The lower GI, rectum, and cecum are the commonest sites. Lipomas can 
be seen any part of the colon. They mostly occur in the rectum and cecum, but familiar 
lesions such as lipomas may be seen in any part of the colon. In SELs, the order was as fol-
lows: Gastrointestinal stromal tumor (GIST), leiomyoma, hemangioma, external compres-
sion, pancreatic rest and granular cell tumor (Table 1). Most benign SELs can be diagnosed 
according to their endoscopic appearance, but findings on routine biopsy are not usually 
that helpful. Benign SELs tumors have a lower detection rate due to the fact that they are 
often small and most patients are asymptomatic. A minority of cases present with abdomi-
nal pain, vomiting, anemia, dysphagia, or gastrointestinal (GI) bleeding and obstruction, 
most of which are likely to result from complications and depending on the site and size 
of the lesion. [3] Among SETs, the malignant potential of GISTs is related to size; how-
ever, malignancy can be detected in smaller lesions [4]. However, SETs can have malig-
nant potential, and it is therefore critical to be able to exclude malignant or premalignant 
lesions [5], the prognoses varying from benign to very aggressive with malignant potential. 
Common benign lesions
1 Lipomas
2 Ectopic pancreas
3 Schwannomas
4 Duplication cysts
Common malignant lesions
1 GIST
2 Lymphoma
3 Metastasis
Table 1. Differential diagnosis of SELs.
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Therefore, proper diagnostic and therapeutic plans are needed for GI SETs. For this  purpose, 
 endoscopic ultrasonography (EUS) is the most accurate diagnostic method [6]. The lesion 
can be evaluated based on its size, layer of origin and echotexture, echogenic homogeneity, 
and the presence of echogenic and anechoic foci. Border, extension to adjacent layers, irreg-
ular margins and invasion into adjacent organs or structures can all be used to help identify 
intramural lesions or direct further management (surgical resection, endoscopic submu-
cosal resection/dissection) or studies (special stains and immunohistochemical evaluation 
of tissue samples) [7, 8]. There are some typical findings for some GI SETs such as lipoma, 
duplication cysts, and ectopic pancreas [7, 9]. However, most hypoechoic SELs make it diffi-
cult to come to a final diagnosis using EUS images alone. Biopsy is necessary for the definite 
diagnosis of GI SETs. Despite obtaining appropriate biopsy specimens, using an endoscopic 
biopsy procedure is often difficult and inconclusive [10]. To overcome the limitations of 
conventional endoscopic biopsy methods, using the bite-on-bite biopsy technique [11], 
EUS-guided cytology or biopsy methods, such as EUS-guided fine-needle aspiration (EUS-
FNA), EUS-guided fine-needle biopsy (EUS-FNB) technique, have now been introduced to 
obtain sufficient tissue. EUS-tissue sampling is a safe procedure for the diagnosis of GI SETs 
and is used for cytological studies. Immunohistochemical staining (IHS) methods are used, 
resulting in good diagnostic yields. Recently, EUS-FNB has been introduced and reportedly 
provides good results for the diagnosis of GI SETs [8]. Although biopsy, including FNA 
and FNB or excision, is required for a definitive diagnosis. Management is generally based 
upon the confidence of diagnosis and whether the lesion causes symptoms. With advanced 
endoscopy technology and the more common use of EUS, the diagnosis and management 
of SETs has been changed.
2. Endoscopic ultrasound
Radial EUS and mini-probe EUS can reveal the precise nature and provide accurate diagnosis 
of GI SETs. SETs such as lipoma, duplication cysts, and ectopic pancreas exhibit some typical 
findings. Forward-viewing linear EUS has been introduced and has been shown to provide 
good image quality and shorter observation times in SETs than oblique-viewing linear EUS 
[12, 42]. EUS is the gold standard for evaluation of SELs with high precision. EUS is able 
to differentiate external compression from intramural lesion and to determine the layer of 
origin [13, 14]. The echogenicity of lesions is different. We can thus differentiate GISTs, leio-
myomas, and schwannomas. The echogenicity of a leiomyoma is equal to the echogenicity 
of proper muscle, while a GIST shows slightly higher echogenicity than that of the proper 
muscle, and a schwannoma shows extremely low echogenicity [2]. In addition, EUS is better 
at providing a more accurate indication of the size of lesion than other modalities. EUS can 
evaluate for regional lymphadenopathy. Tissue biopsy can be obtained. Finally, EUS helps to 
determine appropriate management of the case. Some noninvasive imaging methods, such 
as transabdominal ultrasonography (US), computed tomography (CT), and magnetic reso-
nance imaging (MRI), have been used, but they are often insufficient. With these methods, 
the transition zone (the area where the tumor arises from normal gut wall layers) needs to 
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be examined carefully to determine the layer of origin. The reported accuracy of EUS in 
predicting the pathologic diagnosis of subepithelial lesions showed a wide range, from 45.5 
to 82.9% [14–19]. The sensitivity and specificity of EUS malignant finding is 64 and 80%, 
respectively [6]. However, EUS findings are not sufficient to accurately predict malignancy 
[10]. If tissue was obtained from EUS-guided fine-needle aspiration (EUS-FNA), the diag-
nostic accuracy increased markedly, ranging from 63 to 98% [1, 26–28]. EUS-FNA for SETs 
using a forward-viewing linear EUS has provided good results: full histologic assessment 
rate of 93.4%, sensitivity of 92.8%, specificity of 100% [20, 42]. Tumor size and location are 
important factors for good sampling in EUS-FNA for GI SETs. The diagnostic rate for tumors 
≥4 cm was 100%, but for tumors of 2–4 and <2 cm, the diagnostic rates were only 86% and 
71%, respectively [21, 22]. Using cytology alone, differentially diagnosing GISTs from other 
mesenchymal tumors is not easy. Findings of mitosis in EUS-FNA specimens are known to 
be associated with malignant GISTs [29, 30], Ki-67 staining is helpful in evaluating the aggres-
siveness of GISTs [7, 23, 24]. Many studies have reported the use of various EUS-FNA needles 
to improve diagnostic accuracy. Tissue sampling and diagnostic rates for SETs were similar 
when comparing the use of 22 and 25 G EUS-FNA needles (sampling rate, sensitivity, posi-
tive predictive value, negative predictive value: 100, 55, 100, and 0% for 22 G needles; 100, 64, 
100, and 0% for 25 G needles) [25]. Furthermore, 25 G needles were superior to 22 G needles 
for diagnosing mobile small lesions. A histologic yield of 95% using this needle was similar 
to the 90% achieved in EUS-FNB using 19 G Pro-Core (Cook Endoscopy, Wilson-Salem, NC, 
USA) needles [26]. EUS-FNA with an on-site cytopathologist (rapid on-site cytopathological 
examination) resulted in a 10–29% increase in the adequacy rates of EUS-FNA specimens 
and a 10–15% increase in the diagnostic rate [27, 28]. Recently, EUS-FNB using reverse bevel 
cheese slicer technology has been introduced [29]. A study compared 22 G EUS-FNA and 
22 G EUS-FNB in EUS-guided GI SET sampling. The EUS-FNB group required a signifi-
cantly lower number of needle passes than the EUS-FNA group. The EUS-FNB group had 
higher yields of optimal macroscopic (30% vs. 92%,) and histological (20% vs. 75%,) core 
samples with three needle passes, which resulted in a high diagnostic rate (20% vs. 75%) 
[8]. The EUS helps in deciding whether a lesion should be removed or followed in situ [30]. 
Lesions confined to the mucosal or submucosal layers can be safely removed endoscopically. 
Surgical resection, if needed, is generally recommended for lesions located in muscularis 
propria, although these lesions need to be removed by experienced clinicians. There is mini-
mal risk when using advances in endoscopic techniques such as endoscopic submucosal dis-
section (ESD) [5, 31, 32]. Follow-up EUS is often used in SETs smaller than 2 cm. For small GI 
SETs, follow-up after a 1-year interval is recommended. If the size of the mass is unchanged 
during two serial EUS follow-ups, extended follow-up is suggested [33]. The American 
Gastroenterological Association Institute Technical Review recommended follow-up by EUS 
or endoscopy at regular intervals for gastric SETs smaller than 3 cm [34]. However, in 2010, 
the National Comprehensive Cancer Network has recommended surgical resection of GISTs 
larger than 2 cm because of their malignant potential [35]. Lesions involving the muscularis 
propria are usually removed surgically because the complete endoscopic resection of these 
lesions is associated with the risk of perforation [36]. Endoscopic resection of gastric SETs 
from the muscularis propria (well-margined, endoluminal growth, 2–5 cm in size), results in 
complete endoscopic  resection in 64% of cases [37].
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3. EUS compared to other imaging modalities
Usually US, CT, and MRI are not sensitive enough to detect and characterize smaller 
SELs. Often it is impossible to differentiate them by endoscopy alone. EUS provides diag-
nostic information only for very large SELs. Like CT and MRI, it can also provide useful 
information on perigastric structures and when malignancy and metastasis is suspected. The 
diagnostic accuracy of MDCT is expected to be improved to even higher levels. Overall accu-
racy of MDCT in detection of SELs from a recent study was 78.8–85.3% [38], EUS has a history 
of higher accuracy in detecting and assessing the size and location of SELs comparison to other 
radiological imaging modalities. The narrow differential diagnosis of SELs afforded by the 
use of EUS is more effective than when the decision between observations with surveillance 
in patients with suspected benign lesions or resection when the lesion is likely to be malignant 
is taken (Table 2). In the differentiation between SELs and extraluminal compression, EUS 
also demonstrates a higher accuracy than endoscopy, ultrasonography, and CT. It has been 
reported that US and CT established the diagnosis in only 16% of cases, compared with 100% 
for EUS. In another comparison study of US, CT and EUS reported an accuracy of 22, 28, and 
100%, respectively, in differentiating  subepithelial tumors from extraluminal compression [39].
4. Extramural lesions
When EUS demonstrates the integrity of all gut wall layers between the gut lumen and the 
lesion, it is safe to say that the lesion is an impression caused by an extramural structure. A nor-
mal spleen or splenic hilum is the most common etiology for SELs found to be of extramural 
origin [40]. Other normal anatomic variants such as the left lobe of the liver, the gallbladder, 
the pancreas tail, and enlarged lymph nodes can also sometimes be interpreted as SELs [41]. 
Adjacent structures, such as the aortic arch and vertebrae and enlarged lymph nodes can also 
press on the esophagus. Abnormal structures such as pancreatic pseudocysts, splenic artery 
aneurysm, aortic aneurysm, cystic tumor of the pancreas or liver, colonic tumors, and lym-
phoma [42] may also be interpreted as SELs. When using EUS, at a low frequency of 7.5 MHz, 
the examiner should survey the gross relationship between the extramural structure and the 
gut wall. Then, at a higher frequency of 12 MHz, the outer hyper-echoic serosal layer should 
be observed carefully to determine whether it is intact or disrupted. EUS is very sensitive to 
the identification of these extramural lesions. It has been reported that 11% of these were due 
to pathologic lesions, while others were related to adjacent normal organs or vessels [43].
1 Endoscopy
2 Imaging (US, CT, MRI)
3 EUS with or without tissue acquisition
4 Further observation and surveillance for benign lesions
5 Endoscopic vs. surgical resection for premalignant and malignant lesions
Table 2. The practical approach.
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5. Intramural lesions
5.1. Gastrointestinal stromal tumors (GIST)
GIST lesions originate from the muscular propria, which is the fourth layer, and specifically 
from the interstitial cell of Cajal. The pathophysiology of GIST as result of mutation in the 
KIT gene which codes for the c-Kit protein, a tyrosine kinase receptor and in nearly immu-
nohistochemical 95% positive of CD117 (corresponds to c-kit activation, epitope of kit pro-
tein), and, sometimes, CD34 but negative for desmin. Leiomyomas express smooth muscle 
actin and desmin, and schwannomas produce S-100 protein [42, 44]. Approximately 80% 
of GI mesenchymal tumors are GISTs, and approximately 10–30% of GISTs are malignant. 
GIST lesions have the potential for malignant transformation and distant metastases. GIST 
appeared on endoscopy as submucosal lesions (Figure 1A, B, E). On EUS (Figure 1C, D), a 
GIST is typically a well-circumscribed, hypoechoic, relatively homogeneous mass that can 
arise from either the second hypoechoic layer (muscularis mucosa) or more frequently the 
fourth hypoechoic layer (muscularis propria). In addition to size and mucosal ulcer, other 
EUS characteristics have been considered as possible predictive factors, but size is the only 
consistently definitive predictive factor [45–48]. One study suggested that GISTs have a 
marginal hypoechoic halo and relatively higher echogenicity compared with the adjacent 
muscular layer [49]. Another study reported that the internal hypoechoic feature could be 
suggested as a predictive marker of tumor progression [47]. The presence of two of these 
three features had a positive predictive value of 100% for malignant or borderline-malignant 
tumors [50]. A multicenter study reported that malignancy or indeterminate GIST status 
correlated with the presence of ulceration, tumor size larger than 3 cm, irregular margins, 
and gastric location, but not with hyperechoic or hypoechoic internal foci [51]. With hyper-
enhanced GIST after infusion of ultrasound contrast, in consequence, the contrast-enhanced 
harmonic EUS (CEH-EUS) signal intensity of GIST is higher than other benign lesions [52]. 
In addition, another study reported that prediction of malignant GIST was possible with 
CEH-EUS by identifying intratumoral irregular vessels with 83% accuracy [63]. EUS-guided 
fine-needle aspiration (EUS-FNA) and EUS-guided biopsy (EUS) can be performed for 
immunohistochemical examination to achieve better diagnostic accuracy of GIST [53–62]. 
Risk of malignancy depends on the size, the number of cells at pathological evaluation and 
location (Table 3) If the lesion <2 cm and the mitotic count less than 5/50 HPF, the risk of 
malignancy is very low. A GIST larger 5 cm, 10/50 HPF and small bowel have a much higher 
risk [3, 40, 72, 73]. Pathologists classify GISTs as “very low risk,” “low risk,” “intermediate 
risk,” and “high risk” according to the size of the mass and the mitotic count of the resected 
specimen [50, 63, 64]. Management of the case depends on the size and present symptoms. A 
lesion of more than 1 cm needs more evaluation, EUS, FNA, and FNB or additional surgical 
specimens. Because small (<1 cm), asymptomatic mesenchymal tumors are rarely malignant, 
a close follow-up with EUS may be justified. Referral to a medical oncologist is preferable 
before surgical resection to consider adjuvant therapy with Imatinib (Gleevec) for high risk 
lesions.
Excision is advised when growth of the lesion, a change in the echo pattern, or necrosis is 
noted during yearly follow-up with EUS. Surgical treatment is indicated for lesions >3 cm in 
diameter, with features suggestive of malignancy (Table 4). For lesions between 1 and 3 cm, 
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EUS-FNA can be recommended, or ESD can be chosen as a definite diagnostic and therapeu-
tic tool with some risk of bleeding and perforation (2 to 3% in specialized centers). When the 
lesion is confirmed to be a GIST, the risk of malignant transformation needs to be discussed 
with the patient; more careful follow-up or early resection should then be considered.
Figure 1. GIST: (A, B) Endoscopy shows an ulcerated submucosal lesion in the stomach. (C) EUS image showing 
homogeneous hypoechoic lesion. The lesion is located with the fourth layer, corresponding to the muscularis propria. 
(D) Malignant gastrointestinal stromal tumor (GIST) of the stomach. (E) Endoscopy view of small smooth submucosal 
mass noted in the rectum.
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5.2. Leiomyoma
A leiomyoma is a benign tumor originating from the muscular layers (muscularis propria 
and muscularis mucosa) composed of well-differentiated smooth muscle cells with positive 
immunihistochemical findings for desmin and a smooth muscle action protein and negative 
CD117, CD34, and s100. Leiomyomas arise from muscularis mucosa more frequently than 
do GISTs. True leiomyomas are more commonly found in the esophagus and the small intes-
tine but have been found throughout the GI tract. They rarely occur in the stomach or small 
bowel. In contrast, GISTs are rare in the esophagus and are more common in the stomach 
[65]. The risk of malignant transformation is very rare [3]. They appear by EUS as hypoechoic 
well-circumscribed masses in the muscularis propria or the muscularis mucosae (the fourth 
and second EUS layers, respectively). The approach and management of these depends on 
the size of the lesion. A lesion more than 1 cm in size should be referred to EUS for further 
evaluation. With a lesion <1 cm, annual surveillance with EGD or EUS every 1–2 years should 
take place if the patient is asymptomatic [66]. Leiomyomas appearing similar to GIST on EUS 
require tissue sampling with both histologic and immunohistochemical analysis for better 
diagnosis. The indication of surgical resection symptomatic (bleeding) and if the lesion is 
noted to be growing and enlarged with structural changes during the surveillance period 
(Table 5).
History of iron–deficiency anemia
Ulcerated GIST
Stigmata of recent bleeding
Small bowel (jejunum or ileum)
Lesion larger than 2 cm
If the lesion is noted to be growing during the surveillance period
Table 3. GIST, indication of surgery.
Pathology Muscularis mucosa Submucosa Muscularis propria Serosa
GIST X XXX
Leiomyoma X XX
Pancreatic rest XXX
Carcinoid tumor X XXX
Duplication cyst XXX X
Granular cell tumor XX
Varices XXX
Table 4. Lists of the most common types of subepithelial lesions.
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5.3. Lipoma
Lipomas are common benign tumors composed of mature lipocytes, slow growing fatty 
tumors SELs that originate from the submucosal layer (third layer). They are found inciden-
tally in any part of the GI tract, but more often in the gastric antrum than in the small bowel 
and can be seen more frequently in the lower tract [67, 68]. Endoscopically, most lipomas 
are soft solitary, with a smooth bulge and a yellow hue appearance (Figure 2A, B). They are 
indented when pressed with closed biopsy forceps (pillow or cushion sign) an indication 
highly specific for lipoma with specificity of 98% and low sensitivity of 40% were reported. 
On EUS (Figure 2C, D, E), lipomas characteristically appear as intensely hyperechoic, well 
circumscribed homogeneous lesions with clean regular margins arising from the third layer 
of the GI tract, which corresponds to the submucosa. The characteristic appearance on EUS is 
diagnostic and no further evaluation, including biopsy, is indicated [69, 70]. The endoscopic 
and EUS characteristics make it possible to diagnose lipoma in most cases.
Since there is no malignant potential, those lesions, they do not require biopsy or surgical 
resection or even regular endoscopic surveillance. Jumbo biopsy when performed often 
reveals nothing more than yellowish adipose tissue [71]. Once a lipoma has been confirmed, 
follow-up EUS is not recommended. Extremely rare lipomas can become ulcerated [40, 72]. 
Local excision is then advised for these symptomatic lipomas when associated with bleeding 
or obstruction. Resection is also recommended when it is impossible to distinguish between 
a lipoma and a malignant neoplasm, such as a liposarcoma, even though this lesion is rare in 
the GI tract [73].
5.4. Granular cell tumor
Granular cell tumors (GCT) are rare benign lesions of neural derivation thought to arise from 
Schwann cells as supported by immunophenotypic and ultrastructural evidence. Granular cell 
tumors are SELs usually originated from submucosal layer of GI tract and arise from Schwann 
cell. There are reports of malignant transformation in 2–3% of cases. De Ceglie et al. [74] the 
tumor grows towards the mucosal layer. Approximately 2.7–8.1% of GCTs involve the digestive 
tract, and these tumors are multiple in 5–12% of patients, they are usually found incidentally 
during endoscopy or colonoscopy and are located mostly in the esophagus; other locations 
Risk of malignancy Size Mitotic count
Very low <2 cm <5/50 HPF
Low 2–5 cm <5/50 HPF
Moderate <5 cm 6–10/50 HPF
>5 cm <5/50 HPF
High >5 cm 6-–10/50 HPF
Any size >10/50 HPF
Table 5. Association between risk of malignancy and size and mitotic count.
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Figure 2. Lipoma. (A) Endoscopic view of a small elevated lesion covered with normal mucosa in the stomach. (B) Endoscopic 
view of a large elevated lesion covered with normal mucosa in the duodenum. (C) EUS reveals a homogeneous, hyperechoic 
lesion with smooth borders within the third gastric wall layer. (D) EUS image showed a heterogeneous, hyperchoic lesion 
within the third layer of the duodenal wall layer. (E) EUS reveals a large hyperechoic raised from the third colonic wall layer.
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include the stomach (10%) and rarely the colon or rectum. Endoscopically, they appear as small 
firm, isolated nodules or polyps resembling molar teeth, with normal overlying mucosa hav-
ing a yellow hue (Figure 3A). On EUS (Figure 3B), GCTs appear as hypoechoic, homogeneous 
lesions with smooth margins originating from the second or third layer of the GI tract, which 
corresponds to deep mucosa or submucosa. Mucosal biopsy using a regular forceps is usually 
helpful. The risk of malignancy is low, but the size of the tumor is an important factor. Lesions 
>4 cm increase the risk to around 2–4% [2]. Cytologic or histopathologic evaluation staining 
for S-100 can be helpful in differentiating this tumor [75]. For asymptomatic GCTs that are 
not excised, surveillance with EUS every 1–2 years is recommended to monitor changes in 
size. Local endoscopic snare excision can be performed for small tumors limited to the mucosa 
(Figure 3C).
5.5. Ectopic pancreas
Heterotopic pancreas tissue (aberrant pancreas or ectopic pancreatic tissue)—these terms are 
used to describe ectopic pancreatic tissue lying outside its normal location with no anatomic or 
vascular connection to the pancreas proper. They are typically discovered incidentally during 
endoscopy, surgery, or autopsy, in approximately 1 of every 500 operations performed in the 
Figure 3. Granular cell tumor (GCT) of the esophagus. (A) Small, round, molar tooth-like, polypoid lesion in the 
esophagus. (B) Endosonographic image revealed a homogeneous, hypoechoic lesion with smooth margins is noted 
within the fourth layer. (C) Endoscopic image showed a EMR defect of GCT.
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upper abdomen. The incidence in autopsy series has been estimated to be between 1 and 2% 
and in some reported autopsy series up to 13.7%. About 90% of the lesions are located within 
the stomach, and mainly in the gastric antrum, the duodenum, the small intestine, or any-
where in the GI tract. Most often asymptomatic incidental findings on endoscopy, they have 
been reported to present with nausea, epigastric pain, weight loss, hematemesis, ulceration, 
bleeding, acute pancreatitis and, rarely, gastric cyst formation, outlet obstruction, obstructive 
jaundice, dysphagia, and malignancy [76, 77]. These lesions have essentially no malignant 
potential, but there are rare case reports of adenocarcinoma arising from ectopic tissue [78].
Endoscopically (Figure 4A, B), this will typically be a small nodule with a central area of umbili-
cation at the center of the lesion that corresponds to a draining duct. On deep biopsy sampling 
histologically, the presence of pancreatic acinar tissue will confirm the diagnosis. On EUS (Figure 
4C, D) evaluation, it will have a heterogeneous hypoechoic. EUS features are heterogeneous 
Figure 4. Pancreatic rest: (A and B) Endoscopic image of atypical raised submucosal lesion in the gastric antrum. A large 
umblicated lesion, resembling diffused mucosal lesion (C and D), EUS image (different patient) showing a well defined, 
hypoechoic lesion involving the third gastric layers.
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lesions, mainly hypoechoic or intermediate echogenic lesions located within the submucosal 
layer (the third EUS layer) accompanied by scattered small hyperechoic areas. Generally, an 
anechoic area and fourth layer thickening will accompany the lesions. Anechoic cystic or tubular 
structures within the lesion correlate with ductal structures. However, these lesions may develop 
in any location from the deep mucosal to the serosal layer. The management of aberrant pancreas 
tissue remains controversial. It should be guided by the symptoms and the possibility of malig-
nancy. Asymptomatic lesions do not necessarily require resection and can simply be followed 
up. If there are severe symptoms removal is advised. Endoscopic removal is useful both for accu-
rate diagnosis and treatment, although surgical resection is preferred to endoscopic resection 
when the muscularis propria is involved [79]. Cap-assisted endoscopic mucosal resection is an 
effective manner of obtaining adequate tissue for histologic diagnosis and management [80].
5.6. Carcinoid tumor
Carcinoid tumors are slow-growing neuroendocrine tumors arising from entero-chromaffin-
like (ECL) cells with malignant potential. They may arise at various sites anywhere in the GI 
tract, most commonly the GI tract and lung. GI carcinoid tumors are generally discovered inci-
dentally during endoscopy, surgery, or autopsy from the appendix, rectum, stomach, and small 
intestine, and at least 25% of all carcinoid tumors occur within the small bowel (ileum, followed 
by the jejunum, and then the duodenum). The gastric carcinoid tumors account for 9% of all car-
cinoid tumors [81, 82]. Rectal carcinoids are common and represent approximately 20% of all GI 
carcinoid lesions. Female patients predominate. Carcinoid tumors from  different areas of the GI 
tract will have potentially varying presentation and symptoms. Carcinoid tumors are usually 
asymptomatic, but rare complications include hemorrhage, abdominal pain, intestinal obstruc-
tion, and the endocrine carcinoid syndrome that results from the  secretion of functionally active 
substances. Endoscopically (Figure 5A, B), carcinoid tumors appear as small, round, sessile, or 
polypoid lesions with a smooth surface and a yellow hue. They usually have normal overly-
ing mucosa and seldom ulcerate. Gastric and ileal carcinoids are commonly multiple, whereas 
those arising elsewhere are typically solitary. Deep mucosal biopsy is normally diagnostic. EUS 
(Figure 5C, D, E) appearance of carcinoids is usually that of a homogeneous, well demarcated, 
and mildly hypoechoic or isoechoic mass. These lesions arise from the second layer of the GI 
tract and may invade beyond the third submucosal layer. Usually originating from the deep 
mucosal layer and penetrating into the submucosal layer, they may have the classic “salt and 
pepper” pattern. EUS accurately defines the size and extent of these masses and can guide man-
agement. When the lesion is smaller than 2 cm, does not invade further than the third layer, and 
no adenopathy is noted, endoscopic resection is possible [83, 84] (Figure 5F, Table 6).
5.7. Rectal carcinoid tumors
Rectal carcinoid tumors are frequently discovered during routine screening by colonoscopy. 
The size of the lesion is a key factor in risk for metastasis. Lesions <1 cm have rarely metasta-
sized, and endoscopic resection is potentially curative [85, 86]. Small lesions of <1 cm in size 
that are confined to the submucosa should be removed endoscopically. Larger lesions (>2 cm), 
or lesions with penetration into the muscularis propria layer on EUS, or lesions with enlarged 
regional lymphadenopathy should be referred for surgical resection [87, 88].
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5.8. Varices
Here, we are talking mainly about gastric varices or those in other areas of the small bowel 
requiring EUS evaluation (Figure 6A, B), compared to esophageal varices, which are obvi-
ous by routine endoscopy [89]. Patient history and portal hypertensive gastropathy will 
usually support diagnoses of varices versus other etiologies of SELs. Gastric varices can be 
Symptomatic (bleeding)
If the lesion is noted to be growing and enlarged with structural changes during the surveillance period
Table 6. Indication of surgical resection.
Figure 5. Carcinoid tumor. (A and B) Endoscopic images of a round submucosal lesion in the stomach and duodenal, 
respectively. (C -E) Endosonographic views of a homogeneous, hypoechoic lesions were located in the gastric and duodenum 
within the third layer, corresponding to the submucoal layer. (F) Endoscopy image of post-EMR of duodenal carcinoid.
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 misdiagnosed endoscopically as submucosal tumors or thickened gastric folds. EUS (Figure 
6C) will reveal varices as small, round to oval, and anechoic structures or tubular hypoechoic 
or anechoic structure within the submucosa (the third EUS layer) that demonstrates venous 
flow when evaluated with Doppler. When gastric varices grow larger, they appear as anechoic, 
serpentine, tubular structures with smooth margins, accompanied by perigastric collateral 
vessels. In comparative studies, EUS was shown to be inferior to endoscopy for detecting and 
grading esophageal varices, but it permitted detection of fundic varices earlier and more often 
than endoscopy in patients with portal hypertension. EUS can be one of the interventional 
modalities of bleeding varices. EUS was used in the treatment of varices by making it possible 
to inject a sclerosing agent into perforating veins. EUS is used to guide cyanoacrylate injec-
tion and case reports of EUS-guided coiling of refractory bleeding varices. [90] Also, there is a 
report about transesophageal EUS-guided treatment of gastric fundic varices. This procedure 
was shown to be safe and successful in 96% of cases [91].
Figure 6. Ectopic duodenal varices. (A and B) Endoscopic views of a large bulging mass lesion at the duodenum. (C) EUS 
confirmed large, anechoic, tubular, submucosal vessels with multiple extramural collateral vascular structures.
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5.9. Cyst and duplication cysts
Gastrointestinal duplication cysts are also identified throughout adulthood [92]. The cysts are 
benign lesions resulting from an error in the embryonic development of the foregut and can be 
found either within or adjacent to the wall of the gastrointestinal tract. The cysts can enlarge 
with secretions resulting in mass effect, infection, rupture, or bleeding [92]. The stomach is the 
least common site for GI duplication cysts but they can be anywhere in GI tract. On endoscopy 
appeared as small and smooth subepithelial lesion (Figure 7A) and EUS (Figure 7B–D), cysts 
in the GI tract appear as anechoic sharply demarcated structures, ounded, or ovoid structures 
with dorsal acoustic accentuation originating from the second and third layers. However, 
some may be seen as hypoechoic lesions containing echogenic foci. Cystic submucosal tumors 
can be classified into three EUS types (simple cystic, multicystic, and solid cystic tumors). 
Duplication cysts on EUS appear as anechoic, homogeneous lesions with regular margins aris-
ing from the third layer or extrinsic to the GI wall. The walls of duplication cysts may be seen 
as three or five layer structures because of the presence of the submucosa and the muscle layer 
[93]. Duplication cysts are believed to have a low malignant potential, but some case reports 
have described malignant transformation. Complications are rare and may include dysphagia, 
Figure 7. Esophageal and gastric cysts: (A) Endoscopic view of a small bulge at the mid-esophagus. (B) EUS revealed a 
well-demarcated, round, anechoic, within the third layer of esophageal wall. (C and D) EUS images revealed a sharply 
demarcated, anechoic, ovoid structure within the third gastric wall layer.
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abdominal pain, bleeding, and pancreatitis when the cyst is located near the ampulla of Vater. 
Bronchogenic cysts represent 50–60% of all mediastinal cysts, and they can be diagnosed eas-
ily with EUS as anechoic mass without wall layers. EUS-FNA would cause serious complica-
tions, including cyst infection and mediastinitis. Antibiotic  prophylaxis is therefore needed 
and close attention should be paid to avoid  accidental  instrumentation (Tables 7–9).
5.10. Glomus tumors
A glomus tumor originates from smooth muscle cells of the glomus body and originates from 
modified vascular smooth muscle cells, and peripheral soft tissue, [94]. A glomus tumor of the 
gastrointestinal tract is a rare disease, and most of them are found in the stomach. The majority 
of gastric glomus tumors are benign and found incidentally as a SEL during routine endoscopy. 
However, some malignant gastric glomus tumors and cases of ulcerative bleeding have been 
reported. Contrast-enhanced CT reveals a homogeneous hyperdense enhancement on early 
and delayed phase. On evaluation by EUS, glomus tumors are shown as a circumscribed and 
hypoechoic mass internal heterogeneous echo mixed with hyperechogenic in the third or fourth 
layer [95]. Doppler signals suggest the hypervascularity of these lesions located in the submucosa 
and muscularis propria—also rarely in the serosa (third, fourth, and fifth EUS layers, respec-
tively). Fine-needle aspiration with cytologic and immunohistochemical staining positive for 
smooth muscle actin and vimentin and negative for CD117 help to differentiate this lesion [96].
Lesion <1 cm Annual EGD surveillance
Lesion 1–2 cm Annual EGD surveillance vs. endoscopic resection if there is no deeper penetration to submucosal layer
Lesion >2 cm Surgical resection
Table 7. Management approach [95].
Type I gastric carcinoid tumors are associated with atrophic gastritis, pernicious 
anemia and hypergastrinemia
Low malignant potential
Type II gastric carcinoid tumors are also associated with hypergastrinemia, but 
the high gastrin levels are due to Zollinger-Ellison syndrome or MEN-1 (multiple 
endocrine neoplasia syndrome, type 1)
Intermediate malignant potential
Type III gastric carcinoid tumors (normal gastrin levels) are the sporadic form High malignant potential
Table 8. Gastric carcinoid tumors [115].
Type I and II Endoscopic resection for small lesion, <1–2 cm
Type I and II Surgical resection for large lesions >2 cm or Multiple lesions (>5)
Antrectomy or fundectomy (removal of G-cell or ECL
Surveillance every 6–12 months
Type III lesion (normal gastrin level) Surgical resection with lymph node dissection
Table 9. Management of gastric carcinoid tumors.
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5.11. Inflammatory fibroid polyps
Inflammatory fibroid polyp is a rare benign polypoid lesion that is usually found in the stom-
ach, occasionally in the small bowel, and rarely in the esophagus or large bowel [97]. The 
lesion is located in the second or third layer of the gastric wall, with an intact fourth layer. 
Sometimes the internal echo pattern is heterogeneous or hyperechoic [98].
5.12. Lymphoma
Primary lymphomas of the GI tract are usually B-cell type lymphomas, including diffuse large 
B-cell, mantle cell, Burkitt’s, and mucosa associated lymphoid tissue (MALT) [99]. Endoscopy 
with standard biopsies is often not enough for accurate diagnosis. On EUS, a gastrointestinal 
lymphoma usually appears as a hypoechoic lesion in the deep mucosa or submucosa (second 
or third EUS layer). EUS is of key importance for diagnosis with FNA cab being used for flow 
cytometry [100].
6. Histologic assessment of subepithelial lesions
When the SEL is ulcerated, careful biopsy provides an accurate diagnosis. However, for 
most SELs, the results of endoscopic biopsy are inconclusive [101]. Trials with a bite-on-bite 
 technique have been undertaken [102, 103]. However, the sensitivity, specificity, and accuracy 
of cytological evaluations of intramural lesions are all lower than those for SELs in lymph 
nodes or organs adjacent to the GI tract. It has been reported that the sensitivity of EUS-FNA 
for mediastinal masses, mediastinal lymph nodes, celiac lymph nodes, pancreatic tumors, 
and submucosal tumors was 88, 81, 80, 75, and 60%, respectively [104–107]. Subsequent 
endoscopic resection procedures for these lesions will be difficult. EUS-guided tissue diag-
nosis is useful for patients with GIST who have metastasis (Figure 8A, B). In these studies, 
no significant difference in diagnostic accuracy was noted according to the size of the FNA 
needle, but the 25-G needle easily punctured small mobile SELs and the 19-G needle showed 
excellent differentiation between GIST and leiomyoma by enabling tissue procurement for 
immunohistochemical studies (Figure 8C, D). The average reported accuracy of EUS-FNA in 
the diagnosis of SELs lesions is approximately 80% [108–110]. The development of new EUS-
FNB needles promises better GI SET diagnosis rates [111]. In some later prospective studies, 
however, the diagnostic yield of EUS-TCB in patients with gastric SELs was not better than 
that of EUS-FNA, and the tissue core obtained with EUS-TCB was not sufficient to examine 
for mitotic index in GIST. It is clear though that EUS-TCB can be complementary to EUS-
FNA [112]. Complications of EUS-FNA and EUS-TCB are very rare, but can include infection, 
bleeding and perforation. The newly developed ProCore needle (Cook Endoscopy, Winston-
Salem, NC, USA) or Side-Port needle (Olympus, Tokyo, Japan) both appear promising. Core 
biopsy along with aspiration material is made possible with these types of FNA needles [113]. 
It is important to note that any form of needle biopsy carries the possibility of sampling error, 
and a negative finding does not exclude malignancy in GISTs. This diagnostic method should 
be considered for SETs before determining whether tumors should undergo long-term moni-
toring or surgical resection.
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7. Management of subepithelial lesions
Management of SELs can be guided by EUS findings. Extraluminal compression by adjacent 
organs and benign submucosal lesions such as lipomas or simple cysts do not need further 
treatment or follow-up. Pancreatic rest and inflammatory fibroid polyps can be followed in situ. 
Suspicious lesions, such as carcinoid tumors, can be diagnosed with endoscopic biopsy. Biopsy 
should be avoided in lesions that are suspected varices. For deeply located hypoechoic lesions, 
EUS-FNA, or EUS-TCB can be performed for tissue diagnosis. If resection is planned, ESD can 
be used as a therapeutic tool for small mass lesions arising from the submucosal or inner circu-
lar muscularis propria layer, instead of surgical resection. Surveillance may be appropriate for 
SELs without definite tissue diagnosis in patients who are at high operative risk. If the lesion is 
a suspected GIST, changes in size and echogenicity should be monitored. If the size increases or 
malignant features (echogenic foci, heterogeneity, internal cystic space, irregularity of extralu-
minal margins, and adjacent lymphadenopathy) develop, resection should be recommended. 
The follow-up interval depends on the index of suspicion of the examiner and is usually 1 year. 
When the characteristics of the lesion do not change on two consecutive follow-up examina-
tions with EUS, a longer follow-up interval may be justified [40, 114, 115].
Figure 8. EUS-FNA of a gastric and rectal GIST. (A and B) FNA needle was inserted into the mass and the stylet 
was removed as the needle was moved back and forth within the lesion. (C) Slide reveled H&E 20× Spindle Cell 
Neoplasm. (D) Immunohistochemical stains show a positive reaction of the tumor cells for smooth muscle actin and 
positive of C-KIT.
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8. Summary
The most common SELs have all been discussed in this chapter. Their characteristics have been 
summarized and the appropriate diagnostic techniques, therapeutic modalities and immu-
nohistochemical markers used to help in their identification have been reviewed. Most SELs 
should be referred for EUS evaluation especially if the SEL is more than 1 cm in size. Based on 
the specific EUS outcomes, majority of the cases a presumptive diagnosis can be made. It is the 
best test to help and plays an important role in directing further diagnosis and management. 
EUS-FNA is a good method for tissue diagnosis when a GI SET is suspected. Cytological exami-
nation with IHS is essential for the best diagnostic performance in GI SETs. EUS-TCB is good 
for tissue acquisition, but is associated with some technical challenges. EUS is also plays a major 
role in endoscopic resection because it can enable the examiner to determine the depth and orig-
inating wall layer of the lesion. EUS can also be used in the follow-up lesion if it is not resected.
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